科兴制药：2025年前三季度净利润约1.11亿元

Group 1 - The core viewpoint of the article highlights the financial performance of Kexing Pharmaceutical in Q3 2025, showing significant growth in revenue and net profit [1] - Kexing Pharmaceutical reported a revenue of approximately 1.148 billion yuan for the first three quarters, representing a year-on-year increase of 10.54% [1] - The net profit attributable to shareholders was approximately 111 million yuan, reflecting a substantial year-on-year increase of 547.7% [1] - Basic earnings per share reached 0.56 yuan, marking a year-on-year increase of 522.22% [1] Group 2 - As of the report, Kexing Pharmaceutical has a market capitalization of 7.7 billion yuan [2]